Dinesh Thakur
 "Dinesh Thakur")
Dinesh Thakur
Dinesh Thakur is the co-author of The Truth Pill: The Myth of Drug Regulation in India. A trained chemical engineer, he has held senior positions at Bristol-Myers Squibb Company, Ranbaxy Laboratories, and Infosys Technologies. He turned whistleblower against Ranbaxy Labs after witnessing large scale data fraud at the company. His efforts led to Ranbaxy pleading guilty to violating American law before an American court in 2013. Since 2014, he has advocated for reform of India’s colonial era Drugs & Cosmetics Act, 1940 and has founded an advocacy group called the Citizens for Affordable, Safe & Effective Medicine (CASEM). He received a Bachelors degree in Technology from Osmania University, a Master of Science in chemical engineering from University of New Hampshire, and graduate training from Syracuse University.
Dinesh Thakur is the co-author of The Truth Pill: The Myth of Drug Regulation in India. A trained chemical engineer, he has held senior positions at Bristol-Myers Squibb Company, Ranbaxy Laboratories, and Infosys Technologies. He turned whistleblower against Ranbaxy Labs after witnessing large scale data fraud at the company. His efforts led to Ranbaxy pleading guilty to violating American law before an American court in 2013. Since 2014, he has advocated for reform of India’s colonial era Drugs & Cosmetics Act, 1940 and has founded an advocacy group called the Citizens for Affordable, Safe & Effective Medicine (CASEM). He received a Bachelors degree in Technology from Osmania University, a Master of Science in chemical engineering from University of New Hampshire, and graduate training from Syracuse University.
Dinesh Thakur
India must save the reputation of its pharma industry
When both our trading partners and our own doctors raise questions about the quality of medicines we make, what is the government doing to assuage these valid concerns?
 "India must save the reputation of its pharma industry")
The New Drugs Bill: A missed opportunity for reforms in Ayush
The Bill takes regressive steps on the issue of drug safety
